000162949 001__ 162949
000162949 005__ 20180913060411.0
000162949 0247_ $$2doi$$a10.1111/j.1751-1097.1999.tb03335.x
000162949 022__ $$a0031-8655
000162949 02470 $$2ISI$$a000080359200015
000162949 037__ $$aARTICLE
000162949 245__ $$aStability of the fluorescence measurement of Foscan in the normal human oral cavity as an indicator of its content in early cancers of the esophagus and the bronchi
000162949 260__ $$c1999
000162949 269__ $$a1999
000162949 336__ $$aJournal Articles
000162949 520__ $$aPhotodynamic therapy (PDT) with Foscan (mTHPC) is used to cure early cancers of the esophagus or the tracheobronchial tree. However, fixed PDT parameters (drug dose, light dose, etc.) do not permit an accurate prediction of the tissue damage. Large interpatient fluctuations in tissue drug level, at the time of light application, suggest that the light dose must be adjusted to the drug dose shortly before the PDT. This drug dose can be measured endoscopically by light-induced fluorescence spectroscopy, but this measurement is inconvenient and somewhat difficult. A better test site, yielding comparable information, is needed. The oral cavity seems ideal. However, it first had to be established to what extent the estn. of the drug dose was dependent upon the location of the measurement and the pressure applied to the probe. These measurements prove to be not only correlated to similar measurements in the esophagus or the bronchi but also more consistent and less sensitive to the location and the applied pressure. The buccal mucosa is therefore recommended as a test site for measuring the Foscan fluorescence signal at the time of PDT in the esophagus or the bronchi. This measurement is accurate enough for use in light-dose adjustment.
000162949 6531_ $$a122341-38-2 (Foscan) Role: BPR (Biological process)
000162949 6531_ $$aBSU (Biological study
000162949 6531_ $$aunclassified)
000162949 6531_ $$aBIOL (Biological study)
000162949 6531_ $$aPROC (Process) (Foscan fluorescence measurement stability in human oral cavity as indicator of its content in early esophageal and bronch
000162949 6531_ $$aFoscan fluorescence oral mucosa photodynamic therapy
000162949 6531_ $$aPDT esophageal bronchial cancer Foscan fluorescence
000162949 6531_ $$aFluorometry
000162949 6531_ $$aMouth
000162949 6531_ $$aPhotodynamic therapy (Foscan fluorescence measurement stability in human oral cavity as indicator of its content in early esophageal and bronchial cancers)
000162949 6531_ $$aBronchi (carcinoma
000162949 6531_ $$aFoscan fluorescence measurement stability in human oral cavity as indicator of its content in early esophageal and bronchial cancers)
000162949 6531_ $$aCheek (mucosa
000162949 6531_ $$aFoscan fluorescence measurement stability in human oral cavity as indicator of its content in early esophageal and bronchial cancers)
000162949 6531_ $$aEsophagus (neoplasm
000162949 6531_ $$aFoscan fluorescence measurement stability in human oral cavity as indicator of its content in early esophageal and bronchial cancers)
000162949 700__ $$aZellweger, Matthieu
000162949 700__ $$aGrosjean, Pierre
000162949 700__ $$aMonnier, Philippe
000162949 700__ $$0240886$$aVan Den Bergh, Hubert$$g106613
000162949 700__ $$0241203$$aWagnieres, Georges$$g106697
000162949 773__ $$j89$$k5$$q605-610$$tPhotochemistry and Photobiology
000162949 909C0 $$0252376$$pLPAS
000162949 909CO $$ooai:infoscience.tind.io:162949$$particle
000162949 917Z8 $$x148230
000162949 937__ $$aEPFL-ARTICLE-162949
000162949 973__ $$aEPFL$$rREVIEWED$$sPUBLISHED
000162949 980__ $$aARTICLE